Abstract:Thyroid cancer has emerged as the most rapidly proliferating solid neoplasm. In this study, we included a cohort of patients who underwent sonographic assessment and surgical intervention at the Sir Run Run Shaw Hospital, associated with the School of Medicine at Zhejiang University, spanning from January 2019 to June 2020. Stratification of cases was based on a combination of preoperative ultrasonographic evaluations and postoperative histopathological diagnoses, resulting in three distinct groups: high-risk papillary thyroid carcinoma (PTC) labeled as C1, low-risk PTC designated as C2, and a control group (N) composed of benign thyroid tissue adjacent to the carcinoma. Proteomic and phosphoproteomic analyses were conducted on PTC specimens. The comparative assessment revealed that proteins up-regulated in the C1/N and C2/N groups were predominantly involved in functions such as amino acid binding, binding of phosphorylated compounds, and serine protease activity. Notably, proteins like NADH dehydrogenase, ATP synthase, oxidoreductases, and iron ion channels were significantly elevated in the C1 versus C2 comparative group. Through meticulous analysis of differential expression multiples, statistical significance, and involvement in metabolic pathways, this study identified eight potential biomarkers pertinent to PTC metastasis diagnostics, encompassing phosphorylated myosin 10, phosphorylated proline-directed protein kinase, leucine tRNA synthetase, 2-oxo-isovalerate dehydrogenase, succinic semialdehyde dehydrogenase, ADP/ATPtranslocase, pyruvate carboxylase, and fibrinogen. Therapeutic assays employing metformin, an AMP-activated protein kinase (AMPK) activator, alongside the phosphorylation-specific inhibitor ML-7 targeting Myosin10, demonstrated attenuated cellular proliferation, migration, and invasion capabilities in thyroid cancer cells, accompanied by a reduction in amino acid pools. Cellular colocalization and interaction studies elucidated that AMPK activation imposes an inhibitory influence on Myosin10 levels. The findings of this research corroborate the utility of proteomic and phosphoproteomic platforms in the identification of metastatic markers for PTC and suggest that modulation of AMPK activity, coupled with the inhibition of Myosin10 phosphorylation, may forge novel therapeutic avenues in the management of thyroid carcinoma. SIGNIFICANCE: The significance of our research lies in its potential to transform the current understanding and management of thyroid papillary carcinoma (PTC), particularly in its metastatic form. By integrating both proteomic and phosphoproteomic analyses, our study not only sheds light on the molecular alterations associated with PTC but also identifies eight novel biomarkers that could serve as indicators of metastatic potential.

Multi-Omics Analysis of Fatty Acid Metabolism in Thyroid Carcinoma

Fatty Acid Metabolism as a Potential Therapeutic Target in Thyroid Carcinoma

Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma

Metabolic Changes Associated with Papillary Thyroid Carcinoma: A Nuclear Magnetic Resonance-Based Metabolomics Study.

GC-MS-based Metabolomic Analysis of Human Papillary Thyroid Carcinoma Tissue.

UPLC-Q-TOF/MS-based metabolomics explored the metabolic mechanisms of thyroid cancer in different background

Metabolomics of Papillary Thyroid Carcinoma Tissues: Potential Biomarkers for Diagnosis and Promising Targets for Therapy

Plasma Lipidomics Profiling Reveals Biomarkers for Papillary Thyroid Cancer Diagnosis

Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis

Proteomic and Phosphoproteomic analysis of thyroid papillary carcinoma: Identification of potential biomarkers for metastasis

Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A‐mediated fatty acid oxidative pathway

A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma.

Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer

Protein Profiling Of Papillary Thyroid Carcinoma With And Without Lymph Node Metastasis: A Proteomic Study

Integrated proteomic and metabolomic analysis of plasma reveals regulatory pathways and key elements in thyroid cancer.

Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto's thyroiditis

Stimulated Raman Scattering Microscopy Reveals Aberrant Triglyceride Accumulation in Lymphatic Metastasis of Papillary Thyroid Carcinoma

Large-scale transcriptomic analysis of coding and non-coding pathological biomarkers, associated with the tumor immune microenvironment of thyroid cancer and potential target therapy exploration

The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma

[Preliminary Findings for Metabolite Profiles of Papillary Thyroid Carcinoma and Laryngeal Squamous Cell Carcinoma].

Metabolite Analysis-Aided Diagnosis of Papillary Thyroid Cancer.